Miragen Therapeutics said this week that it has acquired from German biopharmaceutical firm T2cure the exclusive rights to technology and intellectual property related to the in vivo use of microRNA-92 as a therapeutic target.

According to the company, miR-92 is "a key regulator of neo-angiogenesis as part of ischemic disease, which may be relevant to peripheral arterial disease and other cardiovascular disorders."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: gene linked to expansion of the human neocortex, and more.

The National Institute of General Medical Sciences director says changes the agency made have allow it to boost success rates.

Ancient DNA indicates Stone Age, hunter-gather inhabitants of Britain imported wheat.

Joel Achenbach explores at National Geographic why people find science difficult to believe.